probenecid has been researched along with Dementia in 8 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Probenecid was administered to 7 unipolar depressed patients, 7 parkinsonians and 7 extrapyramidal patients with senile dementia matched for age and sex." | 3.66 | Biogenic amine disturbances in cerebrospinal fluid in parkinsonism and unipolar depression: use of the probenecid method. ( Mendlewicz, J; Noel, G; Vanderheyden, JE, 1981) |
| "The diagnosis of Alzheimer's disease (13 patients) and Pick's disease (4 patients) has been made on clinical and radiological grounds." | 1.26 | [Cerebral metabolism of dopamine and of serotonin during Alzheimer and Pick's diseases. Dynamic study by the test using probenecid]. ( Chazot, G; Guard, O; Renaud, B, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vanderheyden, JE | 1 |
| Noel, G | 1 |
| Mendlewicz, J | 1 |
| Meyer, JS | 1 |
| Welch, KM | 1 |
| Deshmukh, VD | 1 |
| Perez, FI | 1 |
| Jacob, RH | 1 |
| Haufrect, DB | 1 |
| Mathew, NT | 1 |
| Morrell, RM | 1 |
| Guard, O | 1 |
| Renaud, B | 1 |
| Chazot, G | 1 |
| Stahl, SM | 1 |
| Thiemann, S | 1 |
| Faull, KF | 1 |
| Barchas, JD | 1 |
| Berger, PA | 1 |
| Gottfires, CG | 1 |
| Roos, BE | 2 |
| Gottfries, CG | 2 |
| Kjällquist, A | 1 |
| Pontén, U | 1 |
| Sundbärg, G | 1 |
| van Woert, MH | 1 |
| Bowers, MB | 1 |
8 other studies available for probenecid and Dementia
| Article | Year |
|---|---|
Biogenic amine disturbances in cerebrospinal fluid in parkinsonism and unipolar depression: use of the probenecid method.
Topics: Aged; Dementia; Depressive Disorder; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1981 |
Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer's disease.
Topics: 5-Hydroxytryptophan; Aged; Alzheimer Disease; Carbidopa; Dementia; Dopamine; Drug Combinations; Fema | 1977 |
[Cerebral metabolism of dopamine and of serotonin during Alzheimer and Pick's diseases. Dynamic study by the test using probenecid].
Topics: Aged; Alzheimer Disease; Brain Chemistry; Dementia; Dopamine; Female; Homovanillic Acid; Humans; Hyd | 1976 |
Neurochemistry of dopamine in Huntington's dementia and normal aging.
Topics: Adult; Aged; Aging; Brain; Dementia; Dopamine; Homovanillic Acid; Humans; Huntington Disease; Male; | 1986 |
Acid monoamine metabolites in cerebrospinal fluid from patients with presenile dementia (Alzheimer's disease).
Topics: Aged; Blood-Brain Barrier; Dementia; Dopamine; Female; Humans; Hydroxyindoleacetic Acid; Male; Middl | 1973 |
[Disturbances of monoamine metabolism in organic presenile and senile dementia].
Topics: Caudate Nucleus; Corpus Striatum; Dementia; Dopamine; Globus Pallidus; Homovanillic Acid; Humans; Hy | 1974 |
Cerebrospinal fluid pH and monoamine and glucolytic metabolites in Alzheimer's disease.
Topics: Affective Symptoms; Aged; Bicarbonates; Carbon Dioxide; Dementia; Female; Glycolysis; Homovanillic A | 1974 |
Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
Topics: Dementia; Dihydroxyphenylalanine; Humans; Hydroxyindoleacetic Acid; Parkinson Disease; Phenylacetate | 1970 |